INCY - Incyte inks peptide-based therapies pact with Nimble Therapeutics

Incyte ([[INCY]] +2.7%) has entered into a collaboration with privately held Nimble Therapeutics to discover peptide therapies across various disease areas.The collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, coupled with its suite of assays to enable faster discovery and optimization of promising compounds for intracellular and extracellular targets.Under the terms of the agreement, Nimble will receive an undisclosed upfront payment, reimbursement of certain research related costs and be eligible for downstream milestone payments and royalties.Incyte has exclusive rights to develop and commercialize any peptides discovered under the collaboration, and an option to further expand to include additional targets.

For further details see:

Incyte inks peptide-based therapies pact with Nimble Therapeutics